Published in Am J Pathol on July 01, 2011
Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet (2013) 1.24
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res (2012) 1.00
Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J Natl Cancer Inst (2014) 0.94
The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease. Hum Mol Genet (2014) 0.89
A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. Oncotarget (2015) 0.82
Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature (2003) 6.48
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene (2006) 2.03
RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res (2005) 1.89
Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Cancer Res (2005) 1.64
RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas. Mol Cell Biol (1996) 1.63
Ras signaling in prostate cancer progression. J Cell Biochem (2004) 1.62
Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization. J Cutan Pathol (2010) 1.52
p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. Oncogene (2003) 1.45
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res (2005) 1.41
The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res (2002) 1.31
Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther (2007) 1.29
The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer. Mol Endocrinol (2007) 1.20
Regulation of cell adhesion and collective cell migration by hindsight and its human homolog RREB1. Curr Biol (2008) 1.10
Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A (1990) 1.09
Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol (1994) 1.09
Novel transcriptional potentiation of BETA2/NeuroD on the secretin gene promoter by the DNA-binding protein Finb/RREB-1. Mol Cell Biol (2003) 1.08
RREB-1 is a transcriptional repressor of HLA-G. J Immunol (2009) 1.05
Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol (2006) 1.05
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. Am J Pathol (2009) 1.00
Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. Mod Pathol (2010) 1.00
Ras responsive element binding protein-1 (RREB-1) down-regulates hZIP1 expression in prostate cancer cells. Prostate (2010) 1.00
DNA damage signalling recruits RREB-1 to the p53 tumour suppressor promoter. Biochem J (2009) 0.98
Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector. Oncogene (2007) 0.96
Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol (2009) 0.95
Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology (2009) 0.94
Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods Enzymol (2008) 0.92
Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol (2010) 0.91
Finb, a multiple zinc finger protein, represses transcription of the human angiotensinogen gene. Int J Mol Med (2004) 0.90
A novel zinc finger protein, Finb, is a transcriptional activator and localized in nuclear bodies. Gene (1997) 0.90
An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients. Dis Markers (2008) 0.86
Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am J Surg Pathol (2009) 0.85
The role of Ras superfamily proteins in bladder cancer progression. J Urol (2003) 0.84
Analysis of the structure and expression of the chicken gene encoding a homolog of the human RREB-1 transcription factor. Gene (1997) 0.80
Cross talk of two Krupple transcription factors regulates expression of the ovine FSH receptor gene. Biochem Biophys Res Commun (2002) 0.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Cancer incidence after localized therapy for prostate cancer. Cancer (2006) 2.52
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol (2008) 2.18
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res (2002) 2.01
Profiling the evolution of human metastatic bladder cancer. Cancer Res (2004) 2.00
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest (2012) 1.92
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res (2005) 1.89
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer (2002) 1.83
CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A (2012) 1.79
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res (2006) 1.75
Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer (2009) 1.69
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res (2007) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res (2010) 1.54
Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol (2009) 1.53
Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res (2009) 1.44
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2010) 1.44
The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res (2006) 1.41
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res (2005) 1.41
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis (2006) 1.33
The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res (2002) 1.31
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther (2007) 1.29
Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res (2008) 1.28
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res (2011) 1.28
Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol (2012) 1.26
Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One (2012) 1.23
Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res (2009) 1.21
PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene (2004) 1.20
Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A (2009) 1.17
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol (2010) 1.17
Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (2008) 1.16
CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res (2012) 1.16
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res (2010) 1.14
Angiogenesis and prostate cancer tumor growth. J Cell Biochem (2004) 1.13
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci (2012) 1.12
Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol (2014) 1.08
Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett (2003) 1.08
Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.08
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics (2012) 1.08
Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol Cancer Ther (2007) 1.07
RhoGDI signaling provides targets for cancer therapy. Eur J Cancer (2010) 1.06
Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology (2003) 1.06
Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res (2010) 1.05
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther (2009) 1.05
Adrenal tumor with caval extension--case report and review of the literature. Scand J Urol Nephrol (2002) 1.04
Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia (2009) 1.03
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res (2009) 1.02
Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol (2009) 1.01
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res (2012) 1.00
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. Am J Pathol (2009) 1.00
Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med (2010) 1.00
Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev (2009) 0.98
RalBP1 is necessary for metastasis of human cancer cell lines. Neoplasia (2010) 0.98
Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest (2013) 0.97
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res (2011) 0.97
Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors. Oncol Nurs Forum (2007) 0.97
Haemangiomas in kidneys with end-stage renal disease: a novel clinicopathological association. Histopathology (2014) 0.96
RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol (2007) 0.95
Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem (2009) 0.95
Family interactions among African American prostate cancer survivors. Fam Community Health (2008) 0.95
Fatigue, weight gain, and altered sexuality in patients with breast cancer: exploration of a symptom cluster. Oncol Nurs Forum (2004) 0.95
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res (2013) 0.94
Glandular neoplasms of the urachus: a report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol (2014) 0.94
Kinetic desorption and sorption of U(VI) during reactive transport in a contaminated Hanford sediment. Environ Sci Technol (2005) 0.93
Cancer cryotherapy: evolution and biology. Rev Urol (2004) 0.93
Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods Enzymol (2008) 0.92
Rho proteins in cell migration and metastasis. Crit Rev Eukaryot Gene Expr (2005) 0.92
Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer. J Biol Chem (2008) 0.92